- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (68)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (28)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (236)
- Breast Cancer (714)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (158)
- Colon Cancer (166)
- Colorectal Cancer (108)
- Endocrine Tumor (4)
- Esophageal Cancer (40)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (2)
- Kidney Cancer (124)
- Leukemia (352)
- Liver Cancer (50)
- Lung Cancer (290)
- Lymphoma (286)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (102)
- Myelodysplastic Syndrome (64)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (102)
- Ovarian Cancer (176)
- Pancreatic Cancer (172)
- Parathyroid Disease (2)
- Penile Cancer (16)
- Pituitary Tumor (6)
- Prostate Cancer (148)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (234)
- Skin Cancer (296)
- Skull Base Tumors (54)
- Spinal Tumor (12)
- Stomach Cancer (58)
- Testicular Cancer (28)
- Throat Cancer (92)
- Thymoma (6)
- Thyroid Cancer (98)
- Tonsil Cancer (32)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (8)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (624)
- Complementary Integrative Medicine (22)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (222)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (122)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (116)
- Molecular Diagnostics (8)
- Pain Management (64)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (874)
- Research (402)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (600)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (402)
- Survivorship (324)
- Symptoms (180)
- Treatment (1762)
Chromatin gets a makeover; review in Cell explains
3 minute read | Published January 31, 2013
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on January 31, 2013
Chromatin, the intertwined histone proteins and DNA that are packaged into chromosomes, has long been recognized as a gatekeeper to the underlying DNA template.
While chromatin is typically on the receiving end of the cell's intricate signaling pathways - culminating in the regulation of gene expression - evidence is emerging to give chromatin a previously unrecognized role: as a dynamic participant that transmits received signals back to other proteins to effect changes in cellular responses.
This week in the journal Cell, faculty from MD Anderson's Department of Molecular Carcinogenesis and Center for Cancer Epigenetics review a number of recent studies highlighting chromatin's role as both receiver and transmitter of signals in various cell functions.
Review authors Sharon Dent, Ph.D. and David Johnson, Ph.D., highlight this growing area of research, which is relevant both for understanding basic cell regulation and for determining how signaling goes awry in diseases such as cancer.
Histone modifications: key players in chromatin signaling
Posttranslational modification of histones is one way that the cell regulates the packing and unpacking of chromatin, which in turn helps to determine whether a gene is activated or repressed.
Multiple modifications (acetylation, methylation, ubiquitination, phosphorylation) of multiple histones (5 major families) combined with a multitude of effects on chromatin give rise to a complex "histone code" that signals the transcriptional machinery to turn genes on or off. In recent years, crosstalk has been observed between different histones, giving rise to further complexity in the histone code.
Most of this research was established in yeast cells, but connections between histone ubiquitination and histone methylation, for example, also occur in human cells. In fact, mutations in a human protein highly related to the yeast histone methyltransferase Set1, called MLL, are involved in leukemia.
This work raises the possibility that histones can signal to non-histone proteins in human cells, and that deregulation of these events caused by MLL mutations might contribute to leukemia development.
Chromatin as a signal receiver and transmitter
Research by Sharon Dent and colleagues revealed for the first time that histone modifications - instead of being an end-point for transcriptional regulation - can actually relay information to non-histone proteins, and that the role of chromatin in these events is not limited to DNA-templated events like gene activation. In a series of yeast experiments, Dent and colleagues showed that a signal through a histone protein regulates another protein called Dam1, which is involved in the separation of chromosomes during cell division.
Communication between H2B and Dam1 was the first such instance of crosstalk observed between histone and non-histone proteins. The signaling connection between a chromatin change and a non-DNA-templated process such as chromosome separation was also new.
The review article highlights additional non-transcriptional signaling events in which chromatin plays a role:
- DNA repair and checkpoint signaling
- Mitotic exit
- Chromosome segregation
New disease targets
Chromatin's new identity as a non-transcriptional signaling agent opens up a plethora of research avenues. The relevance of the yeast work to normal and disease mechanisms in humans needs to be explored. Defining these networks should also provide new strategies and targets for combating diseases that result from disrupted signaling pathways, including cancer.
Additional information
Secret life of chromatin: news release and 2011 Cell paper